$0.97
-0.03 (-2.81%)
Open$1.01
Previous Close$1.00
Day High$1.01
Day Low$0.93
52W High$9.60
52W Low$0.62
Volume—
Avg Volume59.8K
Market Cap6.52M
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,991.3% upside
Current
$0.97
$0.97
Target
$20.24
$20.24
$14.74
$20.24 avg
$23.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.47M | 3.50M |
| Net Income | -124,680 | -125,666 | -103,892 |
| Profit Margin | -3.0% | -2.8% | -3.0% |
| EBITDA | -157,557 | -149,483 | -127,277 |
| Free Cash Flow | -89,797 | -95,523 | -91,369 |
| Rev Growth | +15.0% | +2.0% | +12.9% |
| Debt/Equity | 1.05 | 1.12 | 1.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |